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context: The existing literature on the treatment of pediatric chronic tic disorder (CTD) 
and Tourette syndrome (TS) indicates that both behavioral therapy (BT) and pharmaco-
therapy (PT) are effective for reducing symptoms.
Objective: To evaluate the efficacy of BT compared to psychoeducation (PE) or PT 
for reducing tics and co-occurring symptoms and for improving quality of life (QoL) in a 
sample of youths with CTD and TS.
Design: A 10 weeks, 2 sites (Catania, Rome) randomized controlled trial. Participants 
were randomized to receive one of the following treatments: BT, PE, or PT.
Participants: 110 outpatients aged between 8 and 17 years affected by CTD or TS.
results: Patients in the BT and PT groups showed a significant reduction in the severity 
of tic symptoms, while the PE group did not show any improvement. PT was more 
effective for reducing obsessive compulsive symptoms than BT, while PE group did not 
show any improvement. Both BT and PT groups showed an improvement in most QoL 
domains, whereas no differences were found in the PE group.
conclusions: BT is as effective as pharmacological therapy in the treatment of tic 
disorders in children and adolescents, thus offering an alternative to medications for 
CTD and TS.
Keywords: Tourette syndrome, youth, behavior therapy, pharmacological treatment, psychoeducation
inTrODUcTiOn
Tourette syndrome (TS) and chronic tic disorders (CTD) are neurodevelopmental disorders char-
acterized by the presence of motor tics and/or vocal tics that occur regularly and are present for at 
least 12 months (1). Tic onset typically occurs at an average age of 7 years. Tics are usually preceded 
by premonitory urges (PU), an unpleasant sensory phenomenon that is relieved by performing 
tics (2). The awareness of PU increases with age (2–4) and is strongly predicted by interoceptive 
awareness, with higher PU known to be correlated with higher interoceptive awareness (5). TS and 
CTD are often comorbid with other pathologic conditions, such as obsessive-compulsive disorder 
TaBle 1 | Summary of studies on cognitive BT in TS patients.
authors interventions Patients (n°) Mean age Outcome measures results
Azrin and Peterson (27) HR, WL 10 18.1 Tic frequency video-rating HR > WLHR 93.5% decrease
O’Connor et al. (28) HR/CBT > WL 47 39.1 Tic frequency video-rating HR/CBT > WL
Wilhelm et al. (29) HR, ST 32 36.2 Yale Global Tic Severity Scale (YGTSS) HR > ST
HR: from 30.5 to 19.8
ST: from 26.6 to 26.9
Verdellen et al. (12) HR, ERP 43 20.6 YGTSS HR = ERP
58% ER > 30% reduction; 28% HR > 30% 
reduction
Deckersbach et al. (30) HR, ST 30 35.1 YGTSS HR > ST
HR: 39.3 to 18.3
ST: 27.7 to 26.8
Piacentini et al. (32) HR, ST 126 11.7 YGTSS HR > ST
HR: 6 points reduction;
SP: 3 points reduction
Wilhelm et al. (33) CBT, PE, and ST 122 32 YGTSS CBT > PE and ST
Yates et al. (31) HRT, PE 33 10.96 YGTSS HR: motor tic from 17.65 to 15.12;
PE: motor tic 16.31 to 15.88
HR, habit reversal; WL, waitlist; ST, supportive therapy; ERP, exposure response prevention; CBT, comprehensive behavioral therapy; PE, psychoeducation.
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(OCD), attention deficit hyperactivity disorder (ADHD), autism 
spectrum disorder (ASD), anxiety disorders (AD), and affective 
disorders (6). Several studies have shown that quality of life 
(QoL) is impaired in patients affected by TS and CTD, and that 
the presence of comorbidities is correlated with poorer perceived 
QoL (7, 8).
Habit reversal training (HRT) and exposure and response 
prevention (ERP) have demonstrated success in reducing tics 
(9, 10). Although there are some differences between HRT 
and ERP, both include the interruption of stimulus-response 
sequences (11). HRT is a treatment based on the detection of 
a competing response incompatible with tic execution, thereby 
physically preventing performance of the tic. This therapy is 
combined with other components, such as tic awareness training, 
relaxation training, contingency management, and generalization 
training (12, 13). ERP is based on the development of habitu-
ation to PU, exposing the patients to the unpleasant sensation 
that precedes the tics, and thus, preventing them. Both HRT 
and ERP [hereafter collectively referred to as behavioral therapy 
(BT)] offer the advantage of reducing tics without any significant 
adverse effects. According to the European (9) and Canadian 
(14) clinical guidelines and published US practice parameters 
(15), BT has consistently demonstrated success in reducing tic 
severity and is recommended as a first-line intervention for tics 
and TS. Whether non-pharmacological treatments should be 
preferred as first-line option over pharmacotherapy (PT) is a 
debated issue (16), and the discussion often depends not only on 
tic severity, but also on negative drug-induced side effects and 
practical aspects, including parent’s preference. However, only 
few studies have assessed the efficacy of BT for tic disorders and 
TS in childhood (see Table 1), and none of these have compared 
BT and other interventions to PT.
This study aimed to evaluate whether BT for tics would 
prove superior to psychoeducation (PE) and to pharmacological 
treatment in reducing tics and co-occurring disorders associated 
with the tics in a sample of youths with TS and CTD. The study 
also aimed to compare the efficacy of the three treatments in 
improving the QoL of patients.
MaTerials anD MeThODs
study Design
This study was conducted across two locations, the Child and 
Adolescent Neuropsychiatry Units of Catania University and 
of Roma “La Sapienza” University. This study was performed as 
a controlled trial on children and adolescents with TS or CTD. 
Participants were randomized to receive one of three treatments: 
BT, PE, or PT. The study received approval from the local ethics 
committee of each institution (protocol numbers: Catania n. 612; 
Roma n. 4727). Prior to enrollment, the study personnel provided 
a detailed description of the study procedures and the risks and 
benefits to interested families, after which the parents provided 
written informed consent and the children and adolescents gave 
verbal informed assent.
Participants
Eligible participants were patients aged 8–17 years of age with a 
diagnosis of TS or CTD following the DSM-5 criteria. The inclu-
sion criteria were: tics of moderate severity as measured by the 
Yale Global Tic Severity Scale (YGTSS; >13 for subjects affected 
by TS and >9 for those affected by CTD) (17), and an intelligence 
quotient (IQ) >80. The exclusion criteria included epilepsy, 
cardiovascular disease, a family history of QT prolongation or 
arrhythmia, ASD, schizophrenia spectrum disorder, conduct 
disorder, major depression, psychosis, or addiction.
The assessment was performed by treatment-blind evaluators 
with extensive experience in tic disorders. Comorbid ADHD, 
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OCD, or AD was not considered exclusion criteria unless the 
disorder required immediate treatment or a change in the current 
treatment regimen. Children who were taking anti-tic medication 
prior to enrollment (n. 6) were tapered from their treatments and 
underwent a 4-week washout period before the randomization 
and the baseline assessment. Patients randomized to BT or PE 
treatment were without medication during the study. Children 
comorbid with ADHD did not received stimulant medication 
during this study.
sample size Determination and children 
allocation to groups
As said above, the primary aim of the study was to analyze the 
effect of treatments in reducing tics and co-occurring disorders 
associated with the tics in a sample of youths with TS and CTD, 
and to assess whether BT for tics would prove superior to phar-
macological treatment and PE.
Groups of 23 subjects were necessary to assess treatment 
effects of medium-large size (Cohen’s dz = 0.8) in reducing tics 
and co-occurring disorders within each treatment, using a paired 
Student’s t-test, with power = 0.80, and pairwise alpha = 0.00833 
(corresponding to an experiment wise alpha = 0.05 accounting 
for the six comparisons: time 1 vs time 0 and time 2 vs time 0 for 
any of the three treatment groups).
Groups of 23 subjects were also sufficient to detect differences 
of large size (Cohen’s d = 1.1) in the change over time between 
treatment groups, using a Student’s t-test for independent groups, 
with power = 0.80 and pairwise alpha = 0.00833 (correspond-
ing to an experiment wise alpha =  0.05 accounting for the six 
comparisons: BT vs PT, BT vs PE, and PT vs PE, either for change 
T1–T0 or T2–T0).
Based on the computations reported above, we decided to 
enroll at least 23 subjects in the BT and PE treatment groups, 
and at least 46 in the PT group to account for potential greater 
variability of the outcomes in this group due to the variety of 
drugs and doses administered to children. A total of 110 patients, 
96 affected by TS and 14 by CTD, were randomly assigned to 
the groups BT (n =  26), PT (n =  57), or PE (n =  29), using a 
simple randomization plan based on a random number list and 
the preset unbalanced allocation ratio of1:2:1 among groups.
During the study, there was eight drop-outs: one in the group 
BT (low compliance), two in the group PT (low compliance), and 
five in the group PE (two for low compliance and three requesting 
to begin a drug therapy because of an increase of tic severity).
Overall, 102 patients completed the study: 25 for group BT (14 
ERP, 11 HRT), 53 for PT, and 24 for PE. The average age of the 
participants who completed the study was 11.2 years (SD 2.43), 
with 79 males and 23 females.
interventions
Psychoeducation
Psychoeducation provides information about the features of the 
disorder and its etiology, comorbidities, and prognosis, which are 
explained to the children, parents, and other educators without 
giving advice on symptom management (9). This approach, aimed 
to reinforce coping strategies, reduce anxiety, and emphasize the 
patient’s strengths, was conducted over eight sessions. The first 
two sessions lasted 90 min each, then the following six sessions 
were 60 min each.
Behavioral Therapy
Behavioral therapy was conducted according to the therapist 
manual developed by Verdellen et al. (18). Either HRT or ERP 
were conducted over eight weekly sessions. Sessions were 60 min 
in length, although the first two sessions lasted 90  min. The 
primary components of HRT were tic awareness training and 
competing response training. In awareness training, the therapist 
helps the patient to detect tics, one by one, with self-monitoring. 
A ranking of the patient’s tics is constructed according to tic seve-
rity and level of impairment, and then the patient learns to perform 
a voluntary movement to physically prevent performance of the 
tic during the competing response training. The ERP sessions 
consisted of awareness training, tic detection, exposure to PU, 
and tic suppression. Patients were required to practice at home 
and parents were required to monitor tics for 15 min every day.
For the PT Treatment
For the PT treatment, all randomized patients were assigned 
to a child/adolescent psychiatrist who was responsible for their 
medications for the duration of the study. Drug-naïve children 
took risperidone at a dose ranging between 0.5 and 2 mg. Patients 
that had taken risperidone in the past were treated with aripipra-
zole, at a dose ranging between 2.5 and 10 mg. Those who had 
previously taken risperidone and aripiprazole were treated with 
pimozide, at a dose ranging between 2 and 5 mg.
Procedures
Assessment of the patients was performed at three time points dur-
ing the study, the first at baseline (T0), the second after 10 weeks 
(T1), and the third performed 3 months after the last session of 
BT or PE, or 5  months after beginning PT (T2). At each time 
point, patients were assessed according to YGTSS, Premonitory 
Urge for Tic Scale (PUTS), Diagnostic Confidence Index (DCI), 
Children’s Yale-Brown Obsessive-Compulsive Scale for Children 
(CY-BOCS), Clinical Global Impression Scale- Severity (CGI-S), 
and KIDSCREEN-52. At T0, the Wechsler Intelligence Scale 
for Children (WISC-III) was also administered. At T1 and T2, 
changes in tic severity were evaluated by improvement in the 
CGI-Improvement (CGI-I) scale.
Measures
The Wechsler Intelligence Scale for Children (Third Edition; 
WISC-III) was administered to evaluate the IQ of the participants 
(19). The YGTSS is a clinician-rated scale, considered the gold 
standard in tic measurement. It consists of separate motor and 
vocal tic checklists scored from 0 to 5 on two subscales for motor 
and vocal tics. The tic dimensions assessed included the number, 
frequency, duration, intensity, and complexity. The subscales were 
combined to produce a total tic severity score (ranging from 0 to 
50). Another score ranging from 0 to 50 was assigned for global 
impairment due to tics (17).
The TS DCI is a useful tool in clinical practice that measures 
the likelihood of having TS using a score from 0 to 100 (20).
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The Clinical Global Impression Scale-Severity (CGI-S) and 
Improvement (CGI-I) are observer-rated scales that measure 
illness severity and global improvement or change, respectively. 
The severity is measured on a 7-point scale ranging from 1 to 
7, in which a score of 1 represents normal and 7 are extreme. 
Improvement is measured on a 7-point scale that evaluates clinical 
changes in tics relative to the previous evaluation (T1 vs. T0 and 
T2 vs. T1), with a score of 1 representing very much improved, 4 
representing no change and 7 indicating very much worse (21).
The Children’s Yale-Brown Obsessive-Compulsive Scale is 
a clinician-rated scale that assesses the type and severity of 
obsessive–compulsive symptoms in children. The clinician 
notes the presence of obsessions and compulsions, then rates 
the severity of these symptoms using a 0–4 score for the fol-
lowing categories: number, frequency, intensity, resistance, and 
interference (22).
The premonitory urge for Tics Scale is a self-report measure 
that assesses the severity of premonitory sensations (3).
KIDSCREEN-52 is a scale designed to evaluate health-related 
QoL of children and adolescents aged 8–18 years. KIDSCREEN 
contains 52 items, all scored on a 5-point scale, which measure 
10 dimensions: physical well-being, psychological well-being, 
mood and emotions, parent relations and home life, social sup-
port and peers, school environment, social acceptance (bullying), 
and financial resources (23). Both a child/adolescent version and 
parent/proxy version were administered.
statistical analysis
Statistical analyses were performed using STATA release 8.1 
software. First, the distribution of quantitative variables was 
assessed to determine their deviation from the normal distribu-
tion within each treatment group (Shapiro–Wilk test) and the 
homogeneity of variance among the three treatment groups 
(Levene test). The baseline values of the three treatment groups 
for each variable were compared using the parametric analysis 
of variance (ANOVA) test with one grouping factor (treatment, 
three levels). The three treatment groups were then compared 
with regards to change over time for each of the variables using 
a mixed-model ANOVA with one between-subject factor (treat-
ment) and one within-subject factor (time). The analysis was 
repeated including age at the beginning of the intervention as 
covariate, to account for differences in age at intervention among 
groups. Finally, a mixed-model ANOVA was performed on the 
outcome variables obtained by computing the difference between 
the YGTSS absolute scores at baseline (T0) and the same scores 
at week 10 (T1) or week 22 (T2). The analysis was repeated 
including age at the beginning of the intervention as covariate, to 
account for differences in age at intervention among groups. This 
analysis was also repeated including the baseline value of YGTSS 
or CGI-S as covariates to assess the effect of treatment on YGTSS 
and CGI-GI over time, taking into account the tic severity before 
treatment. The Tukey test was used for multiple comparisons to 
check whether the absolute scores differed significantly between 
the time points (T0 vs. T1, T0 vs. T2) for each treatment group, or 
if the variation in scores differed significantly between treatment 
groups for each time point. In addition, in order to evaluate the 
presence of significant changes in the CGI index as measured 
by CGI-I score, a one sample t-test with Bonferroni correction 
was performed for each treatment group, and at every time 
point assuming a value of 4 as indicative of no change and values 
significantly lower or higher than 4 as indicating improvement 
or worsening, respectively, of the CGI over time (see Section 
Measures).
resUlTs
Baseline
At baseline, some significant differences were found between 
groups; specifically, the mean scores for CGI-S and YGTSS were 
significantly lower in the BT group versus the PT group (p < 0.05 
for both). Moreover, the PT group showed a lower mean score 
for the “mood and emotion” sub-item of KIDSCREEN-52 in 
comparison to the other groups (p < 0.05), while the PE group 
showed lower mean scores for the “financial resources” sub-
item of the parent version of the KIDSCREEN test (p <  0.05; 
Tables 2–4).
YgTss Outcome
In general, patients in the BT and PT groups showed a significant 
reduction in the severity of tic symptoms, as assessed by YGTSS 
scores and sub-scores, at both T1 and T2, while the PE group did 
not show any improvement (Table 2). The variations in YGTSS 
scores are shown in Figure 1. Notably, BT and PT were equally 
effective in reducing YGTSS total and sub-scores, and this effect 
persisted over time. Both BT and PT were significantly more 
effective than PE in reducing YGTSS scores.
clinical global impression scale Outcome
Patients in the BT and PT groups showed an improvement in 
CGI-S scores at both T1 and T2 (p < 0.05) and in CGI-I scores 
at T2 (p < 0.05). The PE group did not show any improvement 
(Table 3).
Moreover, the effect of intervention did not change when 
taking into account age at the beginning of intervention or tic 
severity at baseline expressed as YGTSS or CGI-S scores (for 
details, see Tables S1 and S2 in Supplementary Material).
cY-BOcs Outcome
Pharmacotherapy significantly reduced OCD symptoms at both 
T1 and T2 (p < 0.05). The BT group reduced symptoms at both 
T1 and T2, but not significantly, while the PE group did not show 
any improvement (Table 3).
Premonitory Urge for Tic scale Outcome
Premonitory urges were significantly reduced by PT at T1 
(p < 0.05) and by BT at T2 (p < 0.05). The PE group did not show 
any improvement (Table 3).
KiDscreen-52 Outcome
While both BT and PT groups showed an improvement in 
most QoL domains, as perceived by the patients themselves, 
no differences in QoL were found in the PE group (Table  4). 
Specifically, the PT group showed an improvement in physical 
TaBle 3 | CGI-GI, CGI-I, Children’s Yale-Brown Obsessive-Compulsive Scale for Children (CY-BOCS), Premonitory Urge for Tic Scale (PUTS) outcome (values are 
expressed as absolute scores).
Time Behavioral therapy (BT) (n = 25) 
Mean (sD)
Pharmacotherapy (PT) (n = 50) 
Mean (sD)
Psychoeducation (Pe) (n = 24) 
Mean (sD)
Treatment F  
(df1, df2) p 
Treatment × time F  
(df1, df2)p#
CGI-GI 0
1
2
3.92 (0.99)
3.24 (0.72)*
3.20 (0.87)*
4.47 (0.77)
3.57 (0.75)*
3.51 (0.54)*
4.04 (0.86)
4.08 (0.72)
4.00 (0.66)
F(2.99) = 5.88
p = 0.0039
F(4.198) = 9.93  
p < 0.0001
CGI-Ia 0
1
2
–
2.24 (0.88)*
4.00 (1.32)
–
1.94 (0.89)*
3.74 (1.09) 
–
4.00 (0.42)
3.83 (0.48)
F(2.99) = 30.34
p < 0.0001
F(2.99) = 15.64
p < 0.0001
CY-BOCS 0
1
2
8.08 (8.5)
6.60 (7.14)
5.84 (6.69)
14.36 (12.59)
10.17 (9.44)*
10.23 (9.45)*
8.29 (9.14)
8.92 (10.20)
8.38 (9.77)
F(2.99) = 2.49
p = 0.0884
F(4.198) = 4.53
p = 0.0030
PUTS 0
1
2
14.68 (7.90)
13.00 (8.46)
12.04 (8.41)*
10.89 (6.68)
9.15 (5.21)*
9.75 (6.56)
10.63 (7.57)
10.38 (6.89)
10.13 (6.90)
F(2.99) = 2.25
p = 0.1103
F(4.198) = 1.42
p = 0.2331
*p < 0.05. For all variables, but CGI-I, the comparisons are performed between time 1 or time 2 vs time 0, within each treatment group.
aAsterisk refers to the significance value (with Bonferroni’s correction) of the one sample t-test performed within the particular treatment group and time point, assuming the value of 
4 as hypothetical mean indicative of no change (see Section “Materials and Methods”). Values of CGI-I significantly lower (or higher) than 4 indicate an improvement (or worsening) of 
the clinical global index over time.
#Greenhouse-Geisser correction for the sphericity assumption.
TaBle 2 | Yale Global Tic Severity Scale (YGTSS) outcome (values are expressed as absolute scores).
YgTss Time BT (n = 25) Mean (sD) PT (n = 47) Mean (sD) Pe (n = 24) Mean (sD) Treatment F  
(df1, df2) p
Treatment × time F 
(df1, df2) p#
Motor 0
1
2
13.00 (4.03)
7.72 (3.74)*
8.52 (3.85)*
14.04 (4.07)
9.58 (3.94)*
9.09 (2.93)*
13.00 (4.46)
13.04 (4.45)
12.54 (3.90)
F(2.99) = 5.03 
p = 0.0083
F(4,198) = 15.63  
p < 0.0001
Phonic 0
1
2
7.08 (5.74)
3.8 (4.09)*
3.84 (4.91)*
10.28 (4.46)
6.13 (3.46)*
5.66 (3.23)*
8.92 (4.05)
8.67 (4.04)
8.54 (3.80)
F(2.99) = 7.23 
p = 0.0012
F(4.198) = 9.60  
p < 0.0001
Severity score 0
1
2
19.76 (8.49)
11.44 (6.87)*
12.36 (6.49)*
24.13 (7.50)
15.70 (6.59)*
14.72 (5.10)*
21.96 (7.62)
21.66 (7.55)
20.67 (7.38)
F(2.99) = 7.37 
p = 0.0010
F(4.198) = 15.88  
p < 0.0001
Global impairment 0
1
2
15.48 (11.06)
8.4 (8.43)*
7.6 (8.79)*
12.64 (11.46)
7.73 (7.76)*
7.36 (7.88)*
12.91 (10.82)
12.91 (10.83)
12.45 (10.70)
F(2.99) = 1.22 
p = 0.2999
F(4.198) = 7.06  
p = 0.0002
Total 0
1
2
35.4 (17.78)
19.84 (14.38)*
19.96 (13.68)*
36.38 (16.70)
23.47 (12.64)*
22.26 (11.23)*
34.25 (14.34)
35.00 (14.89)
33.12 (13.88)
F(2,99) = 3.22 
p = 0.0442
F(4.198) = 13.51  
p < 0.0001
*p < 0.05, time 1 or time 2 vs time 0, within each treatment group.
#Greenhouse–Geisser correction for the sphericity assumption.
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well-being, psychological well-being, and self-perception at T2 
(p < 0.05), and in mood and emotions, and autonomy at both 
T1 and T2 (p < 0.05). On the other hand, BT improved physical 
and psychological well-being and autonomy at T1 (p < 0.05) and 
self-perception at both T1 and T2 (p < 0.05). Similarly, patients 
in the BT and PT groups showed an improvement in mean 
scores of QoL across many sub-scores according to feedback 
provided by the parents, while no differences were found in the 
PE group (Table 5). Parents of patients in the BT group reported 
improvement in their child’s QoL domains of psychological 
well-being, mood and emotions, self-perception and social 
support, and peers at both T1 and T2, and for autonomy only 
at T2 (p < 0.05 for all sub-scores). Parents of patients in the PT 
group reported improvement in their child’s QoL domains of 
psychological well-being, mood and emotions and autonomy at 
T2, and in physical well-being and self-perception at both T1 
and T2 (p < 0.05 for all).
DiscUssiOn
This study investigates the efficacy of BT compared with PT and 
PE in reducing tics and tic-related impairment in youths with TS 
or CTD. The study has contributed of new findings in the research 
field on effects of BT for tics.
The results of this trial show that BT and PT are equally 
effective in reducing tic severity as measured by YGTSS total and 
sub-scores and by CGI-S scores. Moreover, this improvement 
persisted over time, at least until the end of the follow-up period 
FigUre 1 | Yale Global Tic Severity Scale score variations (means and SEs) from baseline (T0) to time 1 (Tl) and 2 (T2) * p < 0.05, behavioral therapy (BT) vs 
pharmacotherapy (PT); ** p < 0.01, psychoeducation vs both BT and PT.
TaBle 4 | KIDSCREEN-52 (patients) outcome (values are expressed as absolute scores).
KiDscreen52  
patients sub-tests
Time Behavioral therapy (BT) 
(n = 25) mean (sD)
Pharmacotherapy (PT) 
(n = 47) mean (sD)
Psychoeducation (Pe) 
(n = 24) mean (sD)
Treatment F  
(df1, df2) p
Treatment × time F  
(df1, df2) p#
Physical well-being 0
1
2
19.28 (3.18)
20.04 (3.65)*
19.92 (3.59)
18.40 (5.18)
19.28 (4.58)*
20.02 (4.56)*
20.00 (4.61)
19.63 (4.78)
19.75 (4.69)
F(2.93) = 0.23 
p = 0.7964
F(4.186) = 6.02  
p = 0.0002
Psychological well-being 0
1
2
22.36 (3.36)
24.44 (3.58)*
23.06 (4.80)
21.34 (4.29)
21.94 (4.44)
22.72 (4.37)*
22.72 (4.37)
24.13 (3.60)
23.92 (3.57)
F(2.93) = 1.93 
p = 0.1515
F(4,186) = 2.01  
p = 0.1088
Moods and emotion 0
1
2
28.68 (2.87)
30.04 (2.88)
28.84 (5.44)
24.81 (5.80)
26.00 (5.93)*
27.09 (5.91)*
28.00 (6.01)
28.33 (5.12)
27.88 (5.35)
F(2.93) = 3.62 
p = 0.0306
F(4.186) = 4.72  
p = 0.0027
Self-perception 0
1
2
20.32 (3.70)
22.44 (2.90)*
22.36 (3.11)*
19.06 (3.90)
19.72 (3.85)
20.30 (3.72)*
20.46 (4.42)
20.96 (4.07)
21.08 (4.02)
F(2.93) = 2.62 
p = 0.0780
F(4.186) = 4.06  
p = 0.0108
Autonomy 0
1
2
17.72 (3.03)
19.32 (3.04)*
18.52 (4.36)
17.19 (3.99)
17.94 (3.94)*
18.15 (3.84)*
19.38 (3.88)
19.38 (3.88)
19.38 (3.88)
F(2.93) = 1.57 
p = 0.2138
F(4.186) = 3.36  
p = 0.0198
Social support and peers 0
1
2
23.36 (3.86)
23.56 (3.97)
22.88 (4.52)
22.32 (4.68)
22.83 (4.39)
22.94 (4.32)
22.08 (5.88)
22.29 (5.74)
21.92 (5.58)
F(2.93) = 0.41 
p = 0.6651
F(4.186) = 1.02  
p = 0.3959
*p < 0.05, Time 1 or Time 2 vs Time 0, within each treatment group.
#Greenhouse-Geisser correction for the sphericity assumption.
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(22 weeks). It is worth noting that the differences in tic severity 
between the three groups at baseline did not influence the efficacy 
of the treatments.
These results are in line with data from the literature which 
have highlighted the efficacy of both PT and BT in the treatment 
of tic disorders. Indeed, a large series of studies, including many 
TaBle 5 | KIDSCREEN-52 (parents) outcome (values are expressed as absolute scores).
KiDscreen-52 parents sub-tests Time Behavioral therapy (BT) 
(n = 25) mean (sD)
Pharmacotherapy (PT) 
(n = 47) mean (sD)
Psychoeducation (Pe) 
(n = 24) mean (sD)
Treatment F  
(df1, df2) p
Treatment × time
F (df1, df2) p#
Physical well-being 0
1
2
18.04 (2.88)
18.64 (3.38)
18.52 (3.60)
16.66 (4.57)
17.70 (4.43)*
19.11 (4.22)*
16.67 (4.32)
17.08 (3.94)
16.79 (4.34)
F (2.93) = 0.98
p = 0.3794
F(4.186) = 7.65
p < 0.0001
Psychological well-being 0
1
2
21.32 (3.29)
23.02 (4.36)*
23.84 (4.18)*
21.06 (5.58)
21.74 (5.47)
22.34 (5.09)*
20.54 (5.23)
20.63 (5.27)
20.25 (5.14)
F(2.93) = 1.39
p = 0. 2545
F(4.186) = 5.97
p = 0.0002
Moods and emotion 0
1
2
28.44 (3.71)
30.68 (2.67)*
30.24 (3.18)*
25.34 (9.10)
26.06 (8.99)
27.06 (8.26)*
27.83 (7.97)
28.21 (7.48)
28.33 (7.42)
F(2.93) = 2.11
p = 0.1267
F(4.186) = 2.90
p = 0.0343
Self-perception 0
1
2
19.88 (3.28)
21.2 (3.21)*
21.44 (2.84)*
19.77 (3.74)
20.53 (3.68)*
21.21 (3.62)*
19.54 (3.97)
19.42 (4.03)
19.46 (4.00)
F(2.93) = 1.04
p = 0.3578
F(4.186) = 5.02
p = 0.0018
Autonomy 0
1
2
17.76 (3.31)
18.8 (3.11)
19.56 (3.67)*
17.89 (2.90)
18.66 (3.03)
18.74 (2.88)*
17.08 (3.75)
17.04 (3.72)
17.04 (3.72)
F(2.93) = 2.17
p = 0.1194
F(4.186) = 2.66
p = 0.0458
Social support and peers 0
1
2
19.04 (5.62)
21.88 (3.87)*
21.6 (4.88)*
18.47 (4.75)
19.26 (4.76)
19.36 (4.70)
18.08 (3.78)
18.08 (3.78)
18.00 (3.66)
F(2.93) = 2.81
p = 0.0656
F(4.186) = 4.60
p = 0.0037
*p < 0.05, time 1 or time 2 vs time 0, within each treatment group.
#Greenhouse-Geisser correction for the sphericity assumption.
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randomized controlled trials (RCT), have previously demon-
strated the efficacy of PT in the treatment of tics (24–26). BT is 
also a well-known treatment for patients affected by TS or tic 
disorders of moderate or high severity.
The first report about the efficacy of BT dates back to a paper by 
Azrin and Peterson (27). These authors investigated the efficacy of 
HRT in 10 TS patients aged 6–36 years compared with a waiting 
list and found that all the subjects showed substantial improve-
ment, with a mean percent reduction in tics of 93%. Reduction 
occurred for both vocal and motor tics in children and adults.
O’Connor et al. (28) evaluated the efficacy of a combined treat-
ment (awareness training, relaxation and HRT) on tic severity 
in 76 adult patients with CTD. The authors found a significant 
change in post-treatment measures, with 65% of completers 
reporting control over the tic ranging between 75 and 100%. 
There were also significant changes in measures of self-esteem, 
anxiety, and depression. This study compared efficacy of CBT in 
combination with medication and without medication.
In this study, the efficacy of BT and PT were compared with 
the efficacy of PE, with the first two treatments showing greater 
effectiveness in reducing tic severity when compared with PE.
To date, few previous studies have compared the efficacy of BT 
with different types of psychological treatments, and all of them 
found BT to be effective.
Wilhelm et al. (29) compared with a group of 32 patients with 
TS, the efficacy of HRT with a supportive therapy. The authors 
found a 10.6-point decrease in YGTSS in the group that received 
HRT versus no change in YGTSS in the supportive therapy group. 
Deckersbach et al. (30) compared the efficacy of HRT with a sup-
portive therapy on tics. A reduction in tic severity, demonstrated 
by a 9.4-point decrease from the pre-treatment to mid-treatment 
evaluation (after eight sessions), was reported in patients who 
received HRT, but not in those who received supportive therapy. 
These results remained stable at the 6-month follow up. Both 
groups showed increased life satisfaction and psychosocial 
function.
It is worth noting that the results from our study highlighted 
that only BT and PT are effective treatments in improving patient 
QoL, whereas PE showed no effect on this dimension. This find-
ing suggests that QoL of patients with tic disorders is a more 
sensitive measure to assess the patients’ global functioning than a 
more general index (such as life satisfaction).
To date, few studies have examined the efficacy of BT in pedi-
atric patients. More data are available regarding the efficacy and 
safety in adult patients.
Yates et al. (31) performed a single blind RCT on 33 children 
aged 9–13 years with TS and CTD, in which they compared HRT 
with an educational treatment. An improvement in tic severity 
was found in both groups. Motor tic severity showed a greater 
improvement in the group that received HRT. Both groups 
showed a tendency toward improvement in their perceived QoL.
Piacentini et al. (32) performed a large RCT on 126 children 
and adolescents aged 9–17 years affected by TS or CTD, compar-
ing BT with supportive therapy and education. The YGTSS score 
reduction was significantly higher in the group that received the 
behavioral intervention compared to the control treatment group.
Wilhelm et  al. (33) compared BT for tics with PE and sup-
portive therapy in a multisite RCT performed on 122 adults 
with TS (aged 16–69  years). Eight sessions of comprehensive 
behavioral intervention or eight sessions of supportive treatment 
were delivered over 10 weeks. The main outcome measures were 
YGTSS and CGI, which were rated by a clinician blind to treat-
ment assignment. BT was associated with a significantly greater 
decrease in YGTSS (p < 0.001; effect size = 0.57). Also, 24 out of 
63 subjects (38.1%) in the BT group were rated as having much 
improved or very much improved scores in the CGI-I compared 
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to 6.8% in the control group (p <  0.0001). This large study on 
adults showed that BT is safe and effective.
McGuire et  al. (34) conducted a post-treatment analysis of 
248 participants enrolled in two RCT that examined the efficacy 
of Comprehensive Behavioral Intervention for Tics (CBIT) in 
reducing the severity of tic symptoms when compared to PE and 
supportive therapy (32, 33). The nature of bothersome tics was 
examined and the efficacy of CBIT for common bothersome tics 
was compared to PE and supportive therapy. At baseline, motor 
tics and tics with an urge were rated as being more bothersome 
than vocal tics and tics without PU. This examination suggested 
that CBIT outperformed supportive therapy on several tic char-
acteristics, with the presence of a baseline urge being associated 
with greater tic remission for CBIT.
Only two studies have compared BT to another active behav-
ioral intervention. Piacentini et al. (35) conducted a study on 25 
children comparing HRT to awareness training with the results 
indicating only minimal benefit of HRT over awareness training. 
Verdellen et  al. (12) compared HRT to ERP in a group of 43 
patients affected by TS aged 7–55 years. Both treatments showed 
statistically significant improvement.
Woods et al. (36) conducted a post hoc analysis of the trial by 
Piacentini et al. (32) to test whether BT, in comparison to PE and 
supportive therapy, produced a different response on measures 
of other psychiatric symptoms and/or indices of psychosocial 
functioning. The authors found that, at 6-month post-treatment, 
a positive response to BT was associated with improvement in 
obsessive-compulsive and anxiety symptoms. In our study, BT 
was found to be less effective than pharmacological treatment in 
improving obsessive–compulsive symptoms, although this did 
not reach statistical significance.
To our knowledge, ours is the first study to highlight the 
efficacy of BT in reducing the severity of PU. PUs is unpleasant 
sensory phenomena that play a crucial role in triggering tics. 
Thus, BT may provide an additional advantage in the treatment 
of tic disorders by targeting both the tic symptoms themselves 
and the PU, and may achieve greater improvement of the patient’s 
global functioning.
The main limitations of this study include the short follow-up 
period and the small number of participants in each treatment 
arm. Moreover, the influence of the investigated treatments on 
anxiety and affective symptoms were not analyzed.
cOnclUsiOn
This study highlights that BT is as effective as pharmacological 
therapy in the treatment of tic disorders in children and adoles-
cents. Moreover, BT is effective in reducing PUs and improves 
the QoL of patients. When available, BT should be offered as 
a first-line treatment in children and adolescents with mild to 
moderate tic symptoms.
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